Introduction. According to International Agency for Research on Cancer in 2040, about 3 million new cases of breast cancer (BC) are predicted and about 1 million women are expected to die from this pathology. The aim of the study to assess the impact of COVID-19 on the indicators of the oncological service for breast cancer in Kazakhstan. Material and research methods. The main method was a retrospective study using descriptive, analytical methods of biomedical statistics and data of the Ministry of Health of the Republic of Kazakhstan – form No.7 and 35 regarding BC (ICD 10 - C50) for 2011-2020. Results. For 2011-2020 42,376 new cases of BC and 12,914 deaths from this pathology were registered. The average annual crude incidence rate was 46.4±1.10/0000 (95%CI=44.3-48.5), and increased from 40.8±0.70/0000 (2011) to 51 .3±0.70/0000 in 2019 and then decrease to 44.2±0.70/0000 in 2020 (p<0.001). In dynamics, mortality rates tended to (p<0.001) decrease from 16.1±0.40/0000 (2009) to 11.9±0.40/0000 in 2019 and 11.5± 0.40/0000 in 2020, and the average annual crude mortality rate was 14.2±0.60/0000 (95%CI=13.1-15.3). Indicators of early diagnosis (stage I-II) improved from 73.4% (2011) to 86.9% in 2019, and decreased to 84.2% in 2020. Proportion of patients with stage III decreased (from 20.9% in 2011 to 8.4% in 2019 and to 10.0% in 2020) and stage IV (from 5.6% to 4.2% and 5.0%, respectively), i.e. neglect rates are declining. The indicators of morphological verification improved from 95.7% to 99.4% over the years. Conclusions. As a result of the analysis, an improvement in the indicators of morphological verification, early diagnosis, a decrease in the neglect and mortality rates were established. The trends in 2011-2019 differed significantly from the period from 2011-2020, which is due to the COVID-19 pandemic on the registration of BC.
Nurbek S. Igissin1,2,3, Assem Ya. Toguzbayeva4, Aida Zh. Baibusunova1,2, Zhansaya B. Telmanova1,2,3, Gulnur S. Igissinova4,1, Zarina A. Bilyalova1,3, Daulet M. Baibosynov1,2, Zhanerke R. Azhetova1,2, Serikbay T. Orozbaev2, Kuanysh T. Kulayev5, Yerlan K. Kuandykov5, 1 Central Asian Institute for Medical Research, Astana, the Republic of Kazakhstan; 2 NCJSC «Astana Medical University», Astana, the Republic of Kazakhstan; 3 Eurasian Institute for Cancer Research, Bishkek, the Kyrgyz Republic; 4 NCJSC «Asfendiyarov Kazakh National Medical University», Almaty, the Republic of Kazakhstan; 5 Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, the Republic of Kazakhstan.
1. Мерков А.М., Поляков Л.Е. Санитарная статистика. М.: Медицина. 1974. 384 с. 2. Пак Д.Д., Рассказова Е.А., Ермощенкова М.В. Рак молочной железы: учебник. М.: Триада-Х, 2010. 162 с. 3. Рассказова Е.А., Рожкова Н.И. Скрининг для ранней диагностики рака молочной железы // Исследования и практика в медицине. 2014. № 1. С. 45-51. 4. Семиглазов В.Ф., Нургазиев К.Ш., Арзуманов A.C. Опухоли молочной железы (лечение и профилактика): учебник. М.: Алма-Ата, 2001. 88 с. 5. Стентон Гланц. Медико-биологическая статистика. М.; 1999. 460 с. 6. Afifi A.M., Saad A.M., Al-Husseini M.J., et al. Causes of death after breast cancer diagnosis: A US population-based analysis // Cancer. 2020. N 126. P. 1559-1567. 7. Aguiar S., Baiocchi G., Duprat J.P., et al. Value of preoperative testing for SARS-CoV-2 for elective surgeries in a cancer center during the peak of pandemic in Brazil // J Surg Oncol. 2020. N 122. P. 1293–1295. 8. Alagoz O., Lowry K.P., Kurian A.W., et al. Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling // Journal of the National Cancer Institute. 2021. N 113(11). P. 1484–1494. 9. American Cancer Society. Breast Cancer Early Detection and Diagnosis. URL: accessed 26 April 2022. 10. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2008. N 68(6). P. 394–424. 11. Cavalcante F.P., Novita G.G., Millen E.C., et al. Management of early breast cancer during the COVID-19 pandemic in Brazil // Breast Cancer Res Treat. 2020. N 184. P. 637–647. 12. Chou C.P., Lin H.S. Delayed Breast Cancer Detection in an Asian Country (Taiwan) with Low COVID-19 Incidence // Cancer Manag. Res. 2021. N 13. P. 5899-5906. 13. DeSantis C.E., Fedewa S.A., Goding Sauer A., et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women // CA: a cancer journal for clinicians. 2016. N 66(1). P. 31–42. 14. de Azambuja E., Brandão M., Wildiers H. et al; Belgian Collaborative Group on COVID-19 Hospital Surveillance and the Belgian Society of Medical Oncology (BSMO). Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis // ESMO Open. 2020. N 5(5). P. e000947. 15. Dietz J.R., Moran M.S., Isakoff S.J. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic the COVID-19 pandemic breast cancer consortium // Breast Cancer Res Treat. 2020. doi:10.1007/s10549-020-05644-z. 16. Duffy S.W., Seedat F., Kearins O., et al. The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation // Br. J Cancer. 2022. N 1. P. 1–7. 17. Eijkelboom A.H., de Munck L., Vrancken Peeters M.J.T.F.D., et al. Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study // J Hematol. Oncol. 2021. N 14. P. 64. 18. Ejaz H., Alsrhani A., Zafar A., et al. COVID-19 and comorbidities: Deleterious impact on infected patients // Journal of infection and public health. 2020. N 13(12). P. 1833–1839. 19. Fedewa S.A., Cotter M.M., Wehling K.A., et al. Changes in breast cancer screening rates among 32 community health centers during the COVID-19 pandemic // Cancer. 2021. N 127 (23). P. 4512–4515. 20. Ferlay J., Colombet M., Soerjomataram I., et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods // Int. J Cancer. 2019. N 144(8). P. 1941–1953. 21. Ferlay J., Ervik M., Lam F., et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. URL:, 2018, accessed 27 February 2022. 22. Figueroa J.D., Gray E., Pashayan N., et al. Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium. The impact of the Covid-19 pandemic on breast cancer early detection and screening // Preventive medicine. 2021. N 151. P. 106585. 23. Freer P. E. The Impact of the COVID-19 Pandemic on Breast Imaging // Radiologic clinics of North America 2021. N 59(1). P. 1–11. 24. Kaufman H.W., Chen Z., Niles J., et al. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic // JAMA Netw Open. 2020. N 3:e2017267. 25. Klabunde C.N., Ballard-Barbash R. Evaluating Population-Based Screening Mammography Programs Internationally // Seminars in breast disease. 2021. N 10(2). P. 102–107. 26. London J.W., Fazio-Eynullayeva E., Palchuk M.B., et al. Effects of the COVID-19 pandemic on cancer-related patient encounters // JCO clinical cancer informatics. 2020. N 4. P. 657–665. 27. Maringe C., Spicer J., Morris M., Purushotham A., et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study // The Lancet. Oncology. 2020. N 21(8). P. 1023–1034. 28. Maroni R., Massat N.J., Parmar D., et al. A case-control study to evaluate the impact of the breast screening programme on mortality in England // British journal of cancer. 2021. N 124(4). P. 736–743. 29. Moraliyage H., De Silva D., Ranasinghe W., et al. Cancer in Lockdown: Impact of the COVID-19 Pandemic on Patients with Cancer // The oncologist. 2021. N 26(2). P. e342–e344. 30. Naidich J.J., Boltyenkov A., Wang J.J., et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on imaging case volumes // Journal of the American College of Radiology. 2020. N 17. P. 865-872. 31. Online Statistical Calculator. 32. Rosenberg P.S., Barker K.A., Anderson W.F. Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States // Journal of the National Cancer Institute. 2015. N 107(9). 33. Papautsky E.L., Hamlish T. Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic // Breast Cancer Res Treat. 2020. N 184. P.249–254. 34. Siegel R.L., Miller K.D., Fuchs H.E., et al. Cancer statistics, 2021 // CA Cancer J Clin. 2021. N 71. P. 7–33. 35. Sud A., Torr B., Jones M.E. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study // Lancet Oncol. 2020. doi:10.1016/s1470-2045(20)30392-2. 36. The Law of the Republic of Kazakhstan No. 257-IV of March 19, 2010 “About State statistics”. 37. Wang Q., Berger N.A., Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection // JAMA Oncol. 2021. N 7(2). P. 220-227. 38. WMA Declaration of Helsinki, 2013 – Ethical Principles for Medical Research Involving Human Subjects. 39. Yin K., Singh P., Drohan B. Breast imaging, breast surgery, and cancer genetics in the age of COVID-19 // Cancer. 2020. doi:0.1002/cncr.33113. 40. Zhang H., Han H., He T., et al. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis // J Natl Cancer Inst. 2021. N 113(4). P. 371-380. References:[1-5] 1. Merkov A.M., Polyakov L.E. Sanitarnaya statistika [Sanitary statistics]. M. Meditsina, 1974. 384 p. [in Russian] 2. Pak D.D., Rasskazova E.A., Ermoshchenkova M.V. Rak molochnoi zhelezy: uchebnik. [Breast Cancer: textbook]. Triada-X, 2010, 162 p. [in Russian] 3. Rasskazova E.A., Rozhkova N.I. Skrining dlya rannei diagnostiki raka molochnoi zhelezy [Screening for early diagnosis of breast cancer]. Issledovaniya i praktika v meditsine [Research and practice in medicine]. 2014, 1, pp. 45-51. [in Russian] 4. Semiglazov V.F., Nurgaziev K.Sh., Arzumanov A.C. Opukholi molochnoi zhelezy (lechenie i profilaktika): uchebnik [Breast tumors (treatment and prevention): textbook]. Alma-Ata, 2001, 88 p. [in Russian] 5. Stenton Glants. Mediko-biologicheskaya statistika [Biomedical statistics]. M.; 1999, 460 p. [in Russian]
Number of Views: 38

Key words:

Bibliography link

Igissin N.S., Toguzbayeva A.Ya., Baibusunova A.Zh., Telmanova Zh.B., Igissinova G.S., Bilyalova Z.A., Baibosynov D.M., Azhetova Zh.R., Orozbaev S.T., Kulayev K.T., Kuandykov Ye.K. The impact of COVID-19 on the indicators of the oncological service for breast cancer in Kazakhstan // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 1, pp. 33-41. doi 10.34689/SH.2023.25.1.004

Авторизируйтесь для отправки комментариев